Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPz Cussons Regulatory News (PZC)

Share Price Information for Pz Cussons (PZC)

Share Price is delayed by 15 minutes
Get Live Data
87.40    2.10 (2.46%)
Bid:
87.00
Ask:
88.90
Spread: 1.90 (2.184%)
Market Cap: £367.39m
PZC Live PriceLast checked at - London Stock Exchange

Intraday Pz Cussons Share Chart

Trading Statement

22 Sep 2021 07:00

RNS Number : 5280M
PZ CUSSONS PLC
22 September 2021
 

22 September 2021

 

Returning to growth and continued strategic progress

 

PZ Cussons plc ("PZ Cussons" or the "Group") today issues the following trading update in respect of its first quarter of the new financial year to 31 May 2022, ended 28 August 2021.

 

 

Performance Highlights

 

§ As expected, unprecedented demand for our Hygiene brands at the beginning of the Covid-19 pandemic impacted year-on-year revenue comparisons in the first quarter of FY22.

 

§ Two-year Q1 revenue (1) grew +13%, with growth across each of our core categories of Hygiene, Baby and Beauty and in all geographic regions. Must Win Brands were up +23%.

 

§ One-year Q1 revenue (1) declined -9%, driven by Hygiene. The Baby and Beauty categories showed strong price / mix improvement, with Hygiene held back by unusually low levels of promotional discounting on Carex in the prior year.

 

§ Total business performance improved as the quarter progressed and we returned to growth in August. Assuming no further disruption, we expect to return to growth for Q2.

 

§ Must Win Brands declined -20% versus the prior year. Excluding Carex, revenue grew +4%.

 

- The decline was entirely driven by our Hygiene category, with Carex in the UK experiencing double-digit decline. The UK washing & bathing category has shown encouraging momentum as we emerge from Covid-19 restrictions. Carex is the clear market leader in hand hygiene, with revenue up over 40% versus two years ago.

- Sales of Baby products were flat. Covid-19 restrictions in Indonesia weighed more heavily than expected but are starting to moderate.

- Beauty grew double-digit, including our hair brands recovering from social restrictions.

 

§ Net debt reduced further in the first quarter of the new financial year, down to £23m, due in part to the proceeds from the five:am disposal, further narrowing our Food & Nutrition portfolio.

 

§ Despite the significant inflationary pressure on our cost base, assuming no further cost headwinds or global supply or other Covid-related disruption, we expect to deliver FY22 adjusted profit before tax within the current range of expectations.

 

 

Delivering our new strategy: Building brands for life. Today and for future generations

 

§ Q1 marketing investment increased over 20%, with the majority of the spend on Must Win Brands.

 

§ As input cost pressures increase, we have successfully executed price increases across our brand portfolios in Nigeria and Indonesia. In our developed markets, in addition to more targeted price increases, our Revenue Growth Management focus has been to drive brand equity improvements and efficient levels of price promotion to enable further price / mix improvements.

 

§ Simplification of our Nigerian business, including halving our supplier base and consolidating our distribution centres.

 

§ Continued progress developing capabilities and evolving our culture. Building on improved employee engagement scores we have launched a new company purpose, appointed new senior leaders and started a transformation programme to upgrade our people processes and systems.

 

 

Jonathan Myers, Chief Executive Officer, commented:

 

"The medium-term outlook remains in line with our expectations and we have confidence that our brand and market portfolio will emerge strongly once we cycle through the unprecedented demand for hygiene products at the start of the pandemic.

 

We continue to navigate the well-publicised inflationary pressures on commodities and freight. We have a co-ordinated effort underway to reduce product, manufacturing and logistics costs that the consumer does not value while also accelerating our Revenue Growth Management plans to drive price / mix. Combined with sustained and more effective marketing investment, stronger brand plans and new product innovation, these interventions mean that, assuming no further disruptions, we expect to return to growth for Q2 and to deliver low to mid single-digit revenue growth for the year, in line with our strategic financial framework we outlined at the Capital Markets Day in March. Despite the significant inflationary pressure on our cost base, assuming no further cost headwinds or global supply or other Covid-related disruption, we expect to deliver FY22 adjusted profit before tax within the current range of expectations."

 

Quarter 1

Revenue (£m)

Two-year growth (1)

One-year growth (1)

Europe & Americas

42.4

+7%

(28%)

Asia Pacific

40.4

+3%

(5%)

Africa

47.5

+31%

+15%

Central

1.1

(24%)

(51%)

Group

131.4

+13%

(9%)

 

(1) Revenue growth is quoted on a like-for-like organic basis, after the impact of acquired and disposed of brands or businesses, and at constant currency. Two-year growth rates included due to the short-term distorting effect of Covid-19.

 

Notes to editors

Figures are unaudited, and not subject to review by the Group's auditors

 

Cautionary note regarding forward-looking statements

This announcement contains certain forward-looking statements relating to expected or anticipated results, performance or events. Such statements are subject to normal risks associated with the uncertainties in our business, supply chain and consumer demand along with risks associated with macro-economic, political and social factors in the markets in which we operate. Whilst we believe that the expectations reflected herein are reasonable based on the information we have as at the date of this announcement, actual outcomes may vary significantly owing to factors outside the control of the Group, such as cost of materials or demand for our products, or within our control such as our investment decisions, allocation of resources or changes to our plans or strategy. The Group expressly disclaims any obligation to revise forward-looking statements made in this or other announcements to reflect changes in our expectations or circumstances. No reliance may be placed on the forward-looking statements contained within this announcement.

 

For further enquiries, please contact

Investors Sarah Pollard, PZ Cussons plc - Chief Financial Officer 0161 435 1000

Media Tim Linacre / Guy Scarborough / Bryn Woodward - Instinctif 020 7457 2020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAAURAKUKUUR
Date   Source Headline
28th Sep 20165:30 pmRNSAGM Statement
28th Sep 20167:00 amRNSAGM Trading Statement
8th Sep 20165:30 pmRNSDirector/PDMR Shareholding
1st Sep 20161:11 pmRNSDirector/PDMR Shareholding
2nd Aug 20165:30 pmRNSDirector/PDMR Shareholding
27th Jul 20165:30 pmRNSDirector/PDMR Shareholding
26th Jul 201611:05 amRNSHolding(s) in Company
26th Jul 20167:00 amRNSFinal Results
20th Jul 20165:27 pmRNSHolding(s) in Company
11th Jul 201612:18 pmRNSHolding(s) in Company
6th Jul 201612:52 pmRNSHolding(s) in Company
4th Jul 20167:00 amRNSNotice of Adoption of FRS 101
30th Jun 20165:30 pmRNSDirector/PDMR Shareholding
9th Jun 20167:00 amRNSTrading Statement
6th Jun 20167:00 amRNSDirectorate Change
3rd May 20167:00 amRNSChange to the Board of Directors
28th Apr 20165:30 pmRNSDirector/PDMR Shareholding
26th Apr 20167:00 amRNSChange to the Board of Directors
14th Apr 20167:00 amRNSTrading Statement
8th Apr 20167:00 amRNSDirector/PDMR Shareholding
23rd Mar 20165:30 pmRNSDirector/PDMR Shareholding
26th Jan 20167:00 amRNSInterim Results
31st Dec 201511:42 amRNSDirector/PDMR Shareholding
15th Dec 20158:32 amRNSDirector Declaration
10th Dec 20157:00 amRNSTrading Statement
30th Sep 20155:12 pmRNSDirector/PDMR Shareholding
22nd Sep 20154:48 pmRNSResult of AGM
22nd Sep 20157:00 amRNSAGM Trading Statement
11th Aug 20155:24 pmRNSHolding(s) in Company
6th Aug 20155:30 pmRNSDirector/PDMR Shareholding
23rd Jul 20158:18 amRNSDirector/PDMR Shareholding
21st Jul 20157:00 amRNSFinal Results
30th Jun 20155:30 pmRNSDirector/PDMR Shareholding
11th Jun 20157:00 amRNSTrading Statement
9th Apr 20157:00 amRNSTrading Update
1st Apr 20157:00 amRNSBuy-out of Glanbia Plc's stake in Nutricima JV
30th Mar 20154:44 pmRNSDirector/PDMR Shareholding
13th Feb 201510:42 amRNSDirector/PDMR Shareholding
27th Jan 20157:00 amRNSHalf Yearly Report
5th Jan 20152:27 pmRNSDirector/PDMR Shareholding
10th Dec 20147:00 amRNSTrading Update
1st Oct 20145:30 pmRNSDirector/PDMR Shareholding
24th Sep 20143:20 pmRNSDirector/PDMR Shareholding
23rd Sep 20145:30 pmRNSResult of AGM
23rd Sep 20147:00 amRNSInterim Management Statement
15th Sep 20147:00 amRNSAppointment of joint Corporate Broker
29th Aug 20145:30 pmRNSDirector/PDMR Shareholding
27th Aug 20145:30 pmRNSDirector/PDMR Shareholding
1st Aug 20147:00 amRNSAcquisition of Australian food brand five:am
29th Jul 20147:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.